CNBC Television published this video item, entitled “Cramer on how Eli Lilly could be impacted by mixed Alzheimer’s drug study results” – below is their description.
Eli Lilly said its experimental treatment for Alzheimer’s modestly slowed decline in patients over an 18-month period in a mid-stage study. Lilly has already begun a second study of the treatment. Lilly fell 5.3% in the premarket Monday. CNBC’s Jim Cramer reacts to the news.
CNBC Television YouTube Channel
Got a comment? Leave your thoughts in the comments section, below. Please note comments are moderated before publication.